CJC-1295 Benefits and Side Effects: A Research Guide

CJC-1295 is a tetrasubstituted analog of growth hormone–releasing hormone (GHRH) that exists in two distinct research forms — with DAC (drug-affinity complex) and without DAC — that behave so differently they are essentially two different research tools sharing a name. This guide summarizes the documented benefits, side-effect profile, and how each variant compares to sermorelin, tesamorelin, and ipamorelin in the published literature.

Research Use Only. This article summarizes published preclinical and clinical literature. It is not medical advice or dosing guidance.

What is CJC-1295?

CJC-1295 is built on the GHRH(1-29) backbone — the same active fragment as sermorelin — with four amino-acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that stabilize the peptide against enzymatic degradation. The DAC variant adds a maleimidopropionic acid (MPA) group at the C-terminus that covalently binds circulating serum albumin, dramatically extending the half-life.

• CJC-1295 no-DAC (Mod GRF 1-29): Stabilized GHRH(1-29). Half-life ~30 min. Pulsatile GH release.
• CJC-1295 with DAC: Same backbone plus MPA-albumin binder. Half-life ~6–8 days. Sustained GH/IGF-1 elevation.

Documented research benefits

1. Sustained IGF-1 elevation (DAC variant) The defining property of CJC-1295 DAC is its multi-day half-life. The Phase I trial (Teichman et al., 2006) reported 2–3-fold sustained IGF-1 elevations for 6+ days after a single subcutaneous dose, with weekly dosing producing stable elevation across the dosing interval — a profile not achievable with any other GHRH analog.

2. Pulsatile GH release (no-DAC variant) No-DAC CJC-1295 preserves sermorelin-like pulse architecture but with modestly extended duration per pulse. Research models that depend on GH pulsatility rather than sustained elevation typically prefer no-DAC for this reason.

3. Synergy with GHRPs Both variants are extensively paired with ipamorelin in the published literature. The GHRH-receptor + ghrelin-receptor combination produces synergistic GH release exceeding either alone, and is one of the most replicated stacks in GH-secretagogue research.

4. Body composition signals Animal studies of CJC-1295 DAC report increased lean mass and reduced adiposity over multi-week dosing, consistent with sustained IGF-1 elevation. Human body-composition data is limited — the published Phase I program did not progress through full efficacy trials.

5. Sleep architecture Like other GHRH analogues, no-DAC CJC-1295 shares the slow-wave-sleep–promoting property of native GHRH when administered before sleep.

Side-effect profile in published trials

The CJC-1295 DAC clinical evidence base is small — the Phase I Teichman trial in healthy volunteers is the principal source — but the safety profile reported was favorable at the doses studied.

Common adverse events (DAC) - Injection-site reactions: erythema, pruritus — the most frequent finding - Flushing: transient, particularly after early doses - Headache: mild, intermittent - Mild peripheral edema and arthralgia: consistent with sustained GH/IGF-1 elevation

Glucose handling Sustained IGF-1 elevation with DAC produces measurable but typically mild insulin sensitivity changes — the same pattern documented across the GHRH-analog class. The magnitude is dose-dependent.

The discontinued-program note ConjuChem's CJC-1295 DAC development was discontinued after a single unexplained fatality in a separate trial of a different DAC-modified peptide (CJC-1131). The CJC-1295 trials themselves did not report comparable safety signals, but the program never resumed and remains the largest unanswered safety question in the CJC-1295 literature — researchers should document this when citing the compound.

No-DAC profile No-DAC CJC-1295 has the sermorelin-equivalent safety profile: mild, transient injection-site reactions and occasional flushing dominate the reported events, with no signal for the supraphysiologic-GH side effects.

CJC-1295 (no-DAC) vs sermorelin vs tesamorelin

• Sermorelin (GHRH 1-29): Shortest half-life (~10–20 min). Closest to native GHRH pulses. Largest historical clinical evidence base.
• CJC-1295 no-DAC: Sermorelin backbone + 4 stabilizing substitutions. Half-life modestly extended; pulsatility preserved.
• Tesamorelin (GHRH 1-44): Full GHRH with trans-3-hexenoyl group. Half-life ~26–38 min. The only FDA-approved GHRH analog and the one with the largest clinical efficacy dataset.

All three are pulsatile-class. CJC-1295 DAC is the outlier — it is the only GHRH analog in clinical research that intentionally abolishes pulsatility in favor of sustained elevation.

Reconstitution and storage notes

CJC-1295 (both variants) is supplied lyophilized and reconstituted with bacteriostatic water for research use. Refrigerate at 2–8 °C, protect from light, and follow the working-solution window documented on the batch COA. Avoid repeated freeze–thaw cycles.

Bottom line

CJC-1295 is two research tools in one name. No-DAC is the stabilized sermorelin replacement — pulsatile, short-acting, mechanistically clean, the standard partner for ipamorelin in synergy research. DAC is the only GHRH analog that achieves multi-day sustained IGF-1 elevation, with the trade-offs of an abolished pulsatility profile and a small clinical evidence base.

References

1. Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults. *J Clin Endocrinol Metab*, 2006.
2. Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. *Growth Horm IGF Res*, 2009.
3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. *J Clin Endocrinol Metab*, 2006.
4. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. *Endocrinology*, 2005.